直接抗病毒药物治疗对丙型肝炎患者肝外疾病预后的影响  

Effect of treatment with direct-acting antiviral agents on the prognosis of extrahepatic diseases in patients with hepatitis C

作　　者：王晓燕[1] 张缭云[1] WANG Xiaoyan;ZHANG Liaoyun(Department of Infectious Diseases,The First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院感染病科,太原030001

出　　处：《临床肝胆病杂志》2024年第2期369-373,共5页Journal of Clinical Hepatology

基　　金：山西省科技厅重点研发计划项目(201903D421056)。

摘　　要：HCV感染者的预后不仅取决于肝脏病变,还取决于肝外后遗症。直接抗病毒药物(DAAs)作为当前治疗丙型肝炎的一线用药,使越来越多的患者获得持续病毒学应答及临床治愈,但其对肝外疾病转归的影响尚不清楚。本文就DAAs治疗对丙型肝炎患者肝外疾病预后的影响作一综述,提示丙型肝炎治愈患者仍需进行长期随访监测。The prognosis of patients with hepatitis C virus infection depends not only on liver lesions,but also on extrahepatic sequelae.Direct-acting antiviral agents(DAAs),as the first-line drugs in the treatment of hepatitis C,have helped more and more patients achieve sustained virologic response and clinical cure,but its effect on the prognosis of extrahepatic diseases remains unclear.This article reviews the effect of DAAs treatment on the prognosis of extrahepatic diseases in patients with hepatitis C and points out that long-term follow-up monitoring is still required for patients with hepatitis C after cure.

关 键 词：丙型肝炎 直接抗病毒药物 肝外表现 

分 类 号：R512.63[医药卫生—内科学]